Capital City Trust Co. FL lessened its stake in shares of Danaher Co. (NYSE:DHR – Get Rating) by 3.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,624 shares of the conglomerate’s stock after selling 712 shares during the quarter. Danaher comprises about 1.9% of Capital City Trust Co. FL’s investment portfolio, making the stock its 11th biggest holding. Capital City Trust Co. FL’s holdings in Danaher were worth $6,636,000 at the end of the most recent reporting period.
Other institutional investors have also bought and sold shares of the company. Maryland Capital Advisors Inc. bought a new position in shares of Danaher during the 4th quarter worth about $28,000. Dixon Hughes Goodman Wealth Advisors LLC acquired a new position in Danaher during the fourth quarter worth $29,000. Lee Financial Co acquired a new stake in Danaher in the fourth quarter valued at $30,000. Evolution Advisers Inc. bought a new position in shares of Danaher in the fourth quarter valued at about $32,000. Finally, American National Bank bought a new position in Danaher during the first quarter worth about $35,000. Hedge funds and other institutional investors own 78.42% of the company’s stock.
DHR has been the subject of a number of recent research reports. UBS Group decreased their price target on shares of Danaher from $365.00 to $340.00 in a research note on Sunday, April 24th. Robert W. Baird dropped their price objective on Danaher from $334.00 to $319.00 and set an “outperform” rating for the company in a research note on Friday, April 22nd. Royal Bank of Canada upgraded Danaher from a “sector perform” rating to an “outperform” rating and raised their price target for the company from $299.00 to $310.00 in a report on Wednesday, June 1st. William Blair reissued an “outperform” rating on shares of Danaher in a research report on Friday, April 22nd. Finally, StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Friday, April 22nd. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $336.08.
Danaher (NYSE:DHR – Get Rating) last announced its quarterly earnings results on Thursday, April 21st. The conglomerate reported $2.76 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.11. The firm had revenue of $7.69 billion during the quarter, compared to analysts’ expectations of $7.53 billion. Danaher had a net margin of 21.32% and a return on equity of 18.64%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the company posted $2.52 earnings per share. On average, equities research analysts anticipate that Danaher Co. will post 10.31 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Shareholders of record on Friday, June 24th will be issued a $0.25 dividend. This represents a $1.00 annualized dividend and a yield of 0.40%. The ex-dividend date is Thursday, June 23rd. Danaher’s dividend payout ratio is currently 11.57%.
In related news, EVP Joakim Weidemanis sold 6,500 shares of Danaher stock in a transaction that occurred on Monday, April 25th. The shares were sold at an average price of $255.74, for a total transaction of $1,662,310.00. Following the sale, the executive vice president now directly owns 86,398 shares in the company, valued at approximately $22,095,424.52. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 11.20% of the company’s stock.
Danaher Profile (Get Rating)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.
- Get a free copy of the StockNews.com research report on Danaher (DHR)
- Paychex Continues To Provide Steady And Predictable Results
- The Value Of High-Yielding Walgreens Boots Alliance Deepens
- Why I’m Buying Pfizer And You Should Too
- 3 Reasons Why Snowflake (NYSE: SNOW) Should Be In Your Portfolio
- Now Is The Time To Buy SGH
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.